[Translation] An open, single-arm, two-stage, multicenter Phase II clinical study to evaluate the efficacy and safety of TLC388 as a second-line treatment in subjects with advanced liver cancer
评价疾病控制率(DCR),DCR定义为每两个周期(达6个周期)研究药物治疗后最佳缓释率为完全缓解(CR)、部分缓解(PR)或疾病稳定(SD)(根据实体瘤疗效评价标准[RECIST] v1.1;附录D)并至少维持28天的患者的百分比。
[Translation] The disease control rate (DCR) was evaluated and was defined as the percentage of patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) (according to Response Evaluation Criteria in Solid Tumors [RECIST] v1.1; Appendix D) maintained for at least 28 days after every two cycles (up to 6 cycles) of study drug treatment.